The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis.

ABSTRACT:

Purpose

Three dopamine agonists [bromocriptine, cabergoline, and quinagolide (CV)] have been used for hyperprolactinemia treatment for decades. Several studies have reviewed the efficacy and safety of bromocriptine and cabergoline. However, no systematic review or meta-analysis has discussed the efficacy and safety of CV in hyperprolactinemia and prolactinoma treatment.

Methods

Five medical databases (PubMed, Web of Science, Embase, Scopus, and Cochrane Library) were searched up to 9 May 2022 to identify studies related to CV and hyperprolactinemia. A meta-analysis was implemented by using a forest plot, funnel plot, sensitivity analysis, meta-regression, and Egger's test via software R 4.0 and STATA 12.

Results

A total of 1,211 studies were retrieved from the

SUBMITTER: Zeng Y 

PROVIDER: S-EPMC9902948 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature